The BOLERO‐4 trial [20] demonstrated that a median PFS of 22 months was achieved by combination therapy of everolimus and letrozole as the first‐line treatment in postmenopausal patients with HR‐positive/HER2‐negative advanced breast cancer (Table 2). Here, ERBB2 is linked to breast carcinoma.